Located in Hopewell, N.J., the new facility signifies the first major manufacturing investment for Enzene within the U.S., strengthening the company’s commitment to supporting innovation and supply chain resilience in the country.

This latest funding will bolster the additional investment and private capital and will allow Delpharm to modernize its Boucherville facility to be able to meet the growing demand for injectable drugs.

The strategic investments by the CRDMO, which are aligned with its long-term strategy, will strengthen its integrated oligonucleotide platform and capabilities to delivery ADC solutions.

The location of the facility has been purposefully chosen to be as central as possible to cell and gene therapy companies located across the U.S. and will allow the company to meet growing demand for pDNA development and manufacturing services.

Through this acquisition, ESTEVE will expand its contract development and manufacturing services for small-molecule APIs from pre-clinical through to commercial manufacturing within the U.S.

Marking a strategic move for the company, the expansion will enable acceleration of pre-clinical development of the circVec circular RNA expression data platform.

An official groundbreaking ceremony marked the start of construction on the service provider’s new site in Des Plaines, Ill., which will house a clinical production facility for aseptic manufacturing, new process areas for material preparation and compounding, in addition to other buildings.

To meet growing demand for advanced, domestic biomanufacturing capabilities, Enzene Biosciences is scaling up its soon-to-launch New Jersey facility to 80,000 square feet and integrating its proprietary continuous manufacturing platform.

Located within Bend’s Oregon facility, the four new process development and manufacturing suites will support spray drying and unit operations, helping the company to meet the growing needs of clients in these areas.

The company has added the further sterile fill/finish capacity to the site in response to continued growth in demand for its drug product services.

The new facility adds to the company’s existing infrastructure and is set to provide comprehensive technical support for bioprocessing to biopharmaceutical companies and contract manufacturers.

This latest investment into expanding its manufacturing capabilities reinforces the company’s commitment to the U.S. and enhances its global biomanufacturing network.

The acquisition will provide PCI with a large-scale manufacturing hub on the West Coast of the U.S., complementing its existing global facilities.

Significant funds, in series A & B funding rounds, have been raised from leading investors to advance the company’s two first-in-class monoclonal antibodies targeting inflammation, autoimmunity, and fibrosis.

Over the next five years, Roche will invest USD 50 billion to expand and upgrade existing facilities and build new facilities across its Pharmaceutical and Diagnostics Division in the U.S.

The CRO is expanding its headquarters to include a comprehensive laboratory and rodent vivarium, which enhances its preclinical research infrastructure in the U.S.

Biologics CDMO, Wheeler Bio, has successfully raised USD 35 mn in an oversubscribed Series A-1 funding round. The funds will help the company strengthen its biologics’ manufacturing capabilities, such as planning the development of a large-scale facility.

Canadian CDMO, Delpharm, has secured a USD 42 mn investment from the Canadian Government to enhance the production capacity of its injectables manufacturing facility in Montreal, Canada.

Spanish CDMO, Esteve Química, is investing USD 100 mn to expand its U.S. manufacturing capabilities, focusing on increasing production capacity for high potency APIs (HPAPIs) amid increasing market demands for their use.

Innovation, science, and pharmaceutical services partner, Bend Bioscience, is expanding its Gainesville, Georgia facility with the addition of a commercial-scale spray dryer and a Gerteis drug granulation system.